Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FREM2 | Q5SZK8 | FRAS1-related extracellular matrix protein 2 (ECM3 homolog) | Disease related genesHuman disease related genesPredicted membrane proteins | 1 | Other mediation | 1 | 0.25 | |||
| GFRA1 | P56159 | GDNF family receptor alpha-1 (GDNF receptor alpha-1) (GDNFR-alpha-1) (GFR-alpha-1) (RET ligand 1) (TGF-beta-related neurotrophic factor receptor 1) | Disease related genesPredicted intracellular proteinsPredicted membrane proteins | Fusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 | ||||
| GP132 | Q9UNW8 | Probable G-protein coupled receptor 132 (G2 accumulation protein) | G-protein coupled receptorsPredicted intracellular proteinsPredicted membrane proteins | 7 | Receptor-signaling mediation | 1 | 0.25 | |||
| GPM6B | Q13491 | Neuronal membrane glycoprotein M6-b (M6b) | Predicted membrane proteins | 4 | Adhesion and uptake mediationFusion and delivery mediation | 1 | 0.25 | |||
| GPR39 | O43194 | G-protein coupled receptor 39 | G-protein coupled receptorsPredicted membrane proteinsTransporters | 7 | Acute diabete complication | Clinical-translation mediationReceptor-signaling mediation | 1 | 0.25 | ||
| GRIA2 | P42262 | Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) | Disease related genesHuman disease related genesPotential drug targets | 3 | NeuropathyParkinsonism | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 | ||
| GRID1 | Q9ULK0 | Glutamate receptor ionotropic, delta-1 (GluD1) (GluR delta-1 subunit) | 3 | Clinical-translation mediationReceptor-signaling mediation | 1 | 0.25 | ||||
| HECAM | Q14CZ8 | Hepatic and glial cell adhesion molecule (glialCAM) (Hepatocyte cell adhesion molecule) (Protein hepaCAM) | Disease related genesHuman disease related genesPotential drug targets | 1 | Adhesion and uptake mediation | 1 | 0.25 | |||
| HLAC | P10321 | HLA class I histocompatibility antigen, C alpha chain (HLA-C) (HLA-Cw) (Human leukocyte antigen C) | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||||
| HLAF | P30511 | HLA class I histocompatibility antigen, alpha chain F (CDA12) (HLA F antigen) (Leukocyte antigen F) (MHC class I antigen F) | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||||
| IGSF8 | Q969P0 | Immunoglobulin superfamily member 8 (IgSF8) (CD81 partner 3) (Glu-Trp-Ile EWI motif-containing protein 2) (EWI-2) (Keratinocytes-associated transmembrane protein 4) (KCT-4) (LIR-D1) (Prostaglandin regulatory-like protein) (PGRL) (CD antigen CD316) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Other mediation | 1 | 0.25 | |||
| IL1R2 | P27930 | Interleukin-1 receptor type 2 (IL-1R-2) (IL-1RT-2) (IL-1RT2) (CD121 antigen-like family member B) (CDw121b) (IL-1 type II receptor) (Interleukin-1 receptor beta) (IL-1R-beta) (Interleukin-1 receptor type II) (CD antigen CD121b) [Cleaved into: Interleukin-1 receptor type 2, membrane form (mIL-1R2) (mIL-1RII); Interleukin-1 receptor type 2, soluble form (sIL-1R2) (sIL-1RII)] | Cancer-related genesCD markersPlasma proteins | 1 | Immune system diseaseRheumatoid arthritis | Clinical-translation mediationImmune mediationMetabolism mediation | 1 | 0.25 | ||
| IL2RB | P14784 | Interleukin-2 receptor subunit beta (IL-2 receptor subunit beta) (IL-2R subunit beta) (IL-2RB) (High affinity IL-2 receptor subunit beta) (Interleukin-15 receptor subunit beta) (p70-75) (p75) (CD antigen CD122) | Cancer-related genesCD markersDisease related genes | 1 | Bladder cancerBrain cancerColorectal cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| IL3RA | P26951 | Interleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha) (IL-3R-alpha) (IL-3RA) (CD antigen CD123) | CD markersFDA approved drug targetsPredicted intracellular proteins | 1 | Acute myeloid leukaemiaAsthmaB-cell lymphoma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| ITA6 | P23229 | Integrin alpha-6 (CD49 antigen-like family member F) (VLA-6) (CD antigen CD49f) [Cleaved into: Integrin alpha-6 heavy chain; Integrin alpha-6 light chain; Processed integrin alpha-6 (Alpha6p)] | Cancer-related genesCD markersDisease related genes | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| ITAM | P11215 | Integrin alpha-M (CD11 antigen-like family member B) (CR-3 alpha chain) (Cell surface glycoprotein MAC-1 subunit alpha) (Leukocyte adhesion receptor MO1) (Neutrophil adherence receptor) (CD antigen CD11b) | Cancer-related genesCD markersDisease related genes | 1 | Pancreatic cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| ITAV | P06756 | Integrin alpha-V (Vitronectin receptor) (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain] | Cancer-related genesCD markersFDA approved drug targets | 1 | Colorectal cancerSolid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| JAM1 | Q9Y624 | Junctional adhesion molecule A (JAM-A) (Junctional adhesion molecule 1) (JAM-1) (Platelet F11 receptor) (Platelet adhesion molecule 1) (PAM-1) (CD antigen CD321) | CD markersPlasma proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | |||
| KI2S4 | P43632 | Killer cell immunoglobulin-like receptor 2DS4 (CD158 antigen-like family member I) (Natural killer-associated transcript 8) (NKAT-8) (P58 natural killer cell receptor clones CL-39/CL-17) (p58 NK receptor CL-39/CL-17) (CD antigen CD158i) | 1 | Immune mediation | 1 | 0.25 | ||||
| KLRG1 | Q96E93 | Killer cell lectin-like receptor subfamily G member 1 (C-type lectin domain family 15 member A) (ITIM-containing receptor MAFA-L) (MAFA-like receptor) (Mast cell function-associated antigen) | Predicted intracellular proteinsPredicted membrane proteins | 1 | Idiopathic inflammatory myopathy | Clinical-translation mediationImmune mediation | 1 | 0.25 | ||
| LAMP1 | P11279 | Lysosome-associated membrane glycoprotein 1 (LAMP-1) (Lysosome-associated membrane protein 1) (CD107 antigen-like family member A) (CD antigen CD107a) | CD markersPlasma proteinsPredicted membrane proteins | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| LCAP | Q9UIQ6 | Leucyl-cystinyl aminopeptidase (Cystinyl aminopeptidase) (EC 3.4.11.3) (Insulin-regulated membrane aminopeptidase) (Insulin-responsive aminopeptidase) (IRAP) (Oxytocinase) (OTase) (Placental leucine aminopeptidase) (P-LAP) [Cleaved into: Leucyl-cystinyl aminopeptidase, pregnancy serum form] | EnzymesPredicted membrane proteins | 1 | Fusion and delivery mediationImmune mediationMetabolism mediation | 1 | 0.25 | |||
| LFA3 | P19256 | Lymphocyte function-associated antigen 3 (Ag3) (Surface glycoprotein LFA-3) (CD antigen CD58) | 1 | Pain | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| LPAR5 | Q9H1C0 | Lysophosphatidic acid receptor 5 (LPA receptor 5) (LPA-5) (G-protein coupled receptor 92) (G-protein coupled receptor 93) | G-protein coupled receptorsPredicted membrane proteins | 7 | Receptor-signaling mediation | 1 | 0.25 | |||
| LRC8A | Q8IWT6 | Volume-regulated anion channel subunit LRRC8A (Leucine-rich repeat-containing protein 8A) (HsLRRC8A) (Swelling protein 1) | 4 | Fusion and delivery mediationImmune mediationMetabolism mediation | 1 | 0.25 |